PEB - Pacific Edge Ltd

[850man]

Some positive news. Great to see these updates becoming more frequent too

Investor Update: Q1 FY23 Test Volumes Rise 32%
In the three months to the end of June 2022 Pacific Edge processed 7,055 tests up 13% on the 6,242 tests in the three months to the end of March 2022. The June 2022 figure also represents a 32% increase on the 5,356 tests processed in the same quarter of the prior financial year.


The throughput figures are disclosed in the company’s June 2022 quarterly Investor Update (attached) alongside historical quarterly test volumes starting from the first quarter of the 2021 financial year. These figures show the company has delivered a compound annual growth in test volumes since 2021 of 54%.

[whatsup]

Another brick in the wall.

[pierre]

Some positive news. Great to see these updates becoming more frequent too

Investor Update: Q1 FY23 Test Volumes Rise 32%
In the three months to the end of June 2022 Pacific Edge processed 7,055 tests up 13% on the 6,242 tests in the three months to the end of March 2022. The June 2022 figure also represents a 32% increase on the 5,356 tests processed in the same quarter of the prior financial year.


The throughput figures are disclosed in the company’s June 2022 quarterly Investor Update (attached) alongside historical quarterly test volumes starting from the first quarter of the 2021 financial year. These figures show the company has delivered a compound annual growth in test volumes since 2021 of 54%.

This is very positive news, as is the decision to provide quarterly reporting of test volumes. There is a small fire under the SP at the open that will probably flare up a bit then die away as the day progresses.

The outlook for PEB is starting to brighten and the moves the new CEO is instigating will only keep the business moving forward.

[Brain]

This is very positive news, as is the decision to provide quarterly reporting of test volumes. There is a small fire under the SP at the open that will probably flare up a bit then die away as the day progresses.

The outlook for PEB is starting to brighten and the moves the new CEO is instigating will only keep the business moving forward.

The adoption of Quarterly reporting indicates to me that are very confident of continued growth.

[850man]

and another update! While not huge in the scheme of things, another step in the right direction re adoption of CXbladder

Southern District Health Region Adopts Cxbladder Tests
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it has substantially completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its non-invasive Cxbladder genomic biomarker tests.


The SDHR, which under the new Te Whatu Ora, Health New Zealand, has assumed administrative healthcare responsibility for 326,000 people across Otago and Southland, will deploy Cxbladder Triage into the primary care setting. Deploying into primary care follows the clinical practice model for hematuria evaluation (blood in the urine) established in the Canterbury health region. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.


The agreement with SDHR will mean that 15 of New Zealand’s 20 administrative health regions, which together cover more than 75% of the country’s population, will now have access to the test via public healthcare. Under the primary care model, General Practitioners will be able to order Cxbladder Triage to help safely de-intensify clinical workup for patients presenting with hematuria. In many cases this will reduce the need for secondary referral and an invasive cystoscopy.

[Minerbarejet]

and another update! While not huge in the scheme of things, another step in the right direction re adoption of CXbladder

Southern District Health Region Adopts Cxbladder Tests
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it has substantially completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its non-invasive Cxbladder genomic biomarker tests.


The SDHR, which under the new Te Whatu Ora, Health New Zealand, has assumed administrative healthcare responsibility for 326,000 people across Otago and Southland, will deploy Cxbladder Triage into the primary care setting. Deploying into primary care follows the clinical practice model for hematuria evaluation (blood in the urine) established in the Canterbury health region. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.


The agreement with SDHR will mean that 15 of New Zealand’s 20 administrative health regions, which together cover more than 75% of the country’s population, will now have access to the test via public healthcare. Under the primary care model, General Practitioners will be able to order Cxbladder Triage to help safely de-intensify clinical workup for patients presenting with hematuria. In many cases this will reduce the need for secondary referral and an invasive cystoscopy.

About time too.
Never could understand why the DHB associated with Dunedin and PEB failed to take them up a lot earlier.
Seems daft and it looks like they were forced into it by the new T for2 Aura

[pierre]

About time too.
Never could understand why the DHB associated with Dunedin and PEB failed to take them up a lot earlier.
Seems daft and it looks like they were forced into it by the new T for2 Aura

Agree Miner - it looks like it wont be long now before all health regions in NZ are PEB customers.

Traction is slowly being gained in the US but KP still to really come on stream. I feel confident the next couple of quarterly testing volume reports will show even more progress and over the next year we will start to see some exponential growth.

[Mel]

Agree Miner - it looks like it wont be long now before all health regions in NZ are PEB customers.

Traction is slowly being gained in the US but KP still to really come on stream. I feel confident the next couple of quarterly testing volume reports will show even more progress and over the next year we will start to see some exponential growth.

The ADHB has not adopted CXBladder yet has it?

[pierre]

The ADHB has not adopted CXBladder yet has it?

Counties-Manukau and Waitemata are on board with PEB but I can't find anything confirming the Auckland DHB has adopted CxBladder. Hopefully the new health structure will quickly bring the laggards into line. Auckland probably not keen because it "wasn't invented there".

[Minerbarejet]

Counties-Manukau and Waitemata are on board with PEB but I can't find anything confirming the Auckland DHB has adopted CxBladder. Hopefully the new health structure will quickly bring the laggards into line. Auckland probably not keen because it "wasn't invented there".

Yes - a reasonable assessment Pierre.
Extrapolating out the 15% increase in USA tests over the last quarter and at the same rate for the next three produces, if all paid for, 30,000,000 which should make a sizeable hole in the deficit for the year.